Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis Lennox-Gastaut
Drug Platform Publications Collaborations
Our Mission Directors
Press Releases


Preliminary Pharmacokinetics and Drug StabilityDrug Stability

  • Research done to date indicates that NRPs have very low probability for human toxicity because the peptide is active in the ng/kg to μg/kg range in rodents
  • Dosing only necessary as peripheral administration with potential long interval dosage
  • Biological efficacy (like improvement of motor scores and attenuation of weight loss during neurodegenerative bouts of disease) can be seen without necessity of time consuming “built-up” drug titres in the blood stream
  • Easily formulated peptide drug that can be stored in freezer

Click on the following aspects of the NRP drug platform to read more:

Go To:

Contact Us About Us Research Target Diseases Investors